Shandong Sito Bio-technology (300583.SZ) subsidiary received approval notice for the listing application of dexamethasone chemical raw materials.

date
15:44 13/03/2026
avatar
GMT Eight
Saito Biology (300583.SZ) announced that its controlling subsidiary Shandong Sray Pharmaceutical Co., Ltd. recently received the "Approval Notice for the Marketing Application of Dexamethasone as a Chemical Raw Material Drug" issued by the National Medical Products Administration. Dexamethasone is a long-acting corticosteroid drug that has anti-inflammatory, anti-allergic, and immunosuppressive effects, mainly suitable for allergic and autoimmune inflammatory diseases such as connective tissue diseases, severe bronchial asthma, dermatitis and other allergic diseases, ulcerative colitis, acute leukemia, malignant lymphoma, etc.
Shandong Sito Bio-technology (300583.SZ) announced that its holding subsidiary Shandong Sitrui Pharmaceutical Co., Ltd. recently received the "Approval Notice for the Marketing Application of Dexamethasone Chemical Raw Materials" issued by the National Medical Products Administration. Dexamethasone is a long-acting glucocorticoid drug with anti-inflammatory, anti-allergic, and immunosuppressive effects, mainly used for allergic and autoimmune inflammatory diseases such as connective tissue diseases, severe bronchial asthma, dermatitis, ulcerative colitis, acute leukemia, malignant lymphoma, etc.